Abstract
Pro-inflammatory chemokines are important mediators of inflammation and autoimmune injury. The spatial and temporal expression of chemokines and chemokine receptors in the nephritic kidney suggests that targeting the chemokine system may represent a valuable approach for anti-inflammatory therapy of lupus nephritis. In this review we summarize the available data on the pathogenic role of chemokines and chemokine receptors in lupus nephritis and particularly focus on epidemiological data in lupus patients and interventional studies with chemokine or chemokine receptor antagonists in experimental lupus.
Keywords: Chemokine, chemokine receptors, systemic lupus erythematosus, MRL/lpr mouse, leukocyte recruitment, kidney, polymorphism
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Blockade of Chemokine-Mediated Tissue Injury in Lupus Nephritis
Volume: 6 Issue: 4
Author(s): Volker Vielhauer and Hans-Joachim Anders
Affiliation:
Keywords: Chemokine, chemokine receptors, systemic lupus erythematosus, MRL/lpr mouse, leukocyte recruitment, kidney, polymorphism
Abstract: Pro-inflammatory chemokines are important mediators of inflammation and autoimmune injury. The spatial and temporal expression of chemokines and chemokine receptors in the nephritic kidney suggests that targeting the chemokine system may represent a valuable approach for anti-inflammatory therapy of lupus nephritis. In this review we summarize the available data on the pathogenic role of chemokines and chemokine receptors in lupus nephritis and particularly focus on epidemiological data in lupus patients and interventional studies with chemokine or chemokine receptor antagonists in experimental lupus.
Export Options
About this article
Cite this article as:
Vielhauer Volker and Anders Hans-Joachim, Blockade of Chemokine-Mediated Tissue Injury in Lupus Nephritis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2006; 6 (4) . https://dx.doi.org/10.2174/187153006779025739
DOI https://dx.doi.org/10.2174/187153006779025739 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multimodalities Imaging of Immunoglobulin 4-related Cardiovascular Disorders
Current Cardiology Reviews The Role of Nitric Oxide on Endothelial Function
Current Vascular Pharmacology Use of Anti-Infective Drugs in Rheumatology
Anti-Infective Agents in Medicinal Chemistry Rheumatoid Arthritis: An Evolutionary Force in Biologics
Current Pharmaceutical Design Substance P at the Neuro-Immune Crosstalk in the Modulation of Inflammation, Asthma and Antimicrobial Host Defense
Inflammation & Allergy - Drug Targets (Discontinued) Nano Drug Delivery in Treatment of Oral Cancer, A Review of the Literature
Current Drug Targets Opioid-induced Cardioprotection
Current Pharmaceutical Design Heme Oxygenase-Derived Carbon Monoxide Restores Vascular Function in Type 1 Diabetes
Drug Metabolism Letters Plasminogen Activator Inhibitor-1 in Vascular Thrombosis
Current Drug Targets Uveitis in Horses, Rats and Man: What Do We Learn from Our Pets?
Current Immunology Reviews (Discontinued) The Biological and Clinical Activity of Anti-Malarial Drugs In Autoimmune Disorders
Current Rheumatology Reviews The Interplay between Cofilin and Phospho-Cofilin: Its Role in Maintaining Blood Brain Barrier Integrity
CNS & Neurological Disorders - Drug Targets Systemic Inflammation Induces Endothelial Dysfunction in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued) Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Anti-CD20 Antibody in Primary Sjogren's Syndrome Managemen
Current Pharmaceutical Biotechnology Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Novel Agents Targeting Nitric Oxide
Current Vascular Pharmacology Imaging Neuroinflammation in Ischemic Stroke and in the Atherosclerotic Vascular Disease
Current Vascular Pharmacology Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease
Current Vascular Pharmacology Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design